These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 1349794

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [Abstract] [Full Text] [Related]

  • 23. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH, Bièche I, Hacène K, Lidereau R.
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA.
    Cancer Res; 1992 Mar 01; 52(5):1107-13. PubMed ID: 1737370
    [Abstract] [Full Text] [Related]

  • 26. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
    Zhang DH, Tai LK, Wong LL, Sethi SK, Koay ES.
    Proteomics; 2005 May 01; 5(7):1797-805. PubMed ID: 15825149
    [Abstract] [Full Text] [Related]

  • 27. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE, Pollice AA, Smith CA, Janocko LE, Sweeney L, Brown KA, Singh SG, Gu L, Yakulis R, Lucke JF.
    Clin Cancer Res; 1998 Apr 01; 4(4):913-28. PubMed ID: 9563885
    [Abstract] [Full Text] [Related]

  • 28. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y, Booser DJ, Sneige N.
    Cancer; 2005 May 01; 103(9):1763-9. PubMed ID: 15786420
    [Abstract] [Full Text] [Related]

  • 29. [Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters].
    Lizard-Nacol S, Arnould L, Riedinger JM, Arnal M, Collin F, Guerrin J.
    Bull Cancer; 1994 Sep 01; 81(9):780-4. PubMed ID: 7703567
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H, Lehr HA.
    Breast Cancer Res; 2005 Sep 01; 7(2):R256-66. PubMed ID: 15743506
    [Abstract] [Full Text] [Related]

  • 32. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.
    Kury FD, Schneeberger C, Sliutz G, Kubista E, Salzer H, Medl M, Leodolter S, Swoboda H, Zeillinger R, Spona J.
    Oncogene; 1990 Sep 01; 5(9):1403-8. PubMed ID: 1699198
    [Abstract] [Full Text] [Related]

  • 33. Risk of breast cancer according to the status of HER-2/neu oncogene amplification.
    Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET.
    Cancer Epidemiol Biomarkers Prev; 2000 Jan 01; 9(1):65-71. PubMed ID: 10667465
    [Abstract] [Full Text] [Related]

  • 34. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
    Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI.
    Cancer Res; 2002 Mar 01; 62(5):1481-8. PubMed ID: 11888924
    [Abstract] [Full Text] [Related]

  • 35. Increased erbB-2 gene copies and expression in multiple stages of breast cancer.
    Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR.
    Cancer Res; 1990 Oct 15; 50(20):6701-7. PubMed ID: 2208136
    [Abstract] [Full Text] [Related]

  • 36. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
    Purnomosari D, Aryandono T, Setiaji K, Nugraha SB, Pals G, van Diest PJ.
    Biotech Histochem; 2006 Oct 15; 81(2-3):79-85. PubMed ID: 16908432
    [Abstract] [Full Text] [Related]

  • 37. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA.
    van de Vijver MJ, Mooi WJ, Wisman P, Peterse JL, Nusse R.
    Oncogene; 1988 Feb 15; 2(2):175-8. PubMed ID: 3285295
    [Abstract] [Full Text] [Related]

  • 38. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M, Nasir A, Aman Z, Ahmad T, Samad A.
    J Ayub Med Coll Abbottabad; 2008 Feb 15; 20(3):23-6. PubMed ID: 19610508
    [Abstract] [Full Text] [Related]

  • 39. HER-2/neu oncogene expression in advanced breast cancer.
    Krogerus LA, Leivonen M.
    Cancer Detect Prev; 2001 Feb 15; 25(1):1-7. PubMed ID: 11270416
    [Abstract] [Full Text] [Related]

  • 40. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.
    Jimenez RE, Hussain M, Bianco FJ, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP, Grignon DJ.
    Clin Cancer Res; 2001 Aug 15; 7(8):2440-7. PubMed ID: 11489824
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.